Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies

Objective: REACH-2 and REACH were randomized, placebo-controlled, double-blind, multicenter phase 3 trials which showed survival benefits of ramucirumab treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). We evaluated the efficacy and safety of ra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chia-Jui Yen, Masatoshi Kudo, Ho-Yeong Lim, Chih-Hung Hsu, Arndt Vogel, Giovanni Brandi, Rebecca Cheng, Ioana Simona Nitu, Paolo Abada, Yanzhi Hsu, Andrew X. Zhu, Yoon-Koo Kang
Formato: Artigo
Idioma:Inglês
Publicado em: Karger Publishers 2020-05-01
Colecção:Liver Cancer
Assuntos:
asian patients
hepatocellular carcinoma
ramucirumab
Acesso em linha:https://www.karger.com/Article/FullText/506946
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados